Can Full Body MRI Be Used for Cancer?

“If I already have cancer, is a full body MRI still useful?”

The short answer is yes. In Australia, full body MRI can play a meaningful role in cancer care. But the more useful answer is understanding how and when it fits, and just as importantly, where its limitations and variability lie.

Where Full Body MRI Fits in Australian Cancer Care

In Australia, full body MRI is used in oncology settings for:

Initial staging, to understand where cancer is present in the body and the overall tumour burden. This is important step as this can guide best treatment options. Initial staging scan typically occurs after the initial biopsy confirming cancer. Depending on the sub-type of cancer detected, one or more full body imaging tests are recommended. These can be a combination of PET/CT, full-body CT, nuclear medicine bone scan or full body MRI.
Monitoring treatment response, such as observing how tumours change over time. Like PET/CT, full-body MRI can also be a quantitative scan through changes in the Apparent Diffusion Coefficient (ADC). The ADC metric quantifies changes in tumour cell death (apoptosis), and is another useful tool in characterising benign lesions from malignant.
Surveillance imaging, tracking stability or progression. This is application is particularly useful after curative treatment to monitor for late re-occurrence (metastasis).

This is not about replacing other imaging. It is about using the right tool, or combination of tools, to answer the clinical question as clearly as possible.

Why Some Patients Consider Full Body MRI

One of the most common reasons patients explore MRI is that it does not use ionising radiation.

This tends to be a consideration for:

Younger patients, including children and those diagnosed with early onset cancer.
Individuals on longer treatment pathways
Individuals who want to minimise cumulative radiation exposure

That said, avoiding radiation alone should not determine the imaging choice. Clinical appropriateness remains the priority.

MRI Is Less Dependent on Tumour Biology

One of the key differences between MRI and PET imaging is what they rely on to detect disease.

PET (Positron Emission Tomography) is nuclear imaging test that uses radioactive-labeled agents which targets tumour biology (e.g. receptor expression or increased metabolic activity) to detect cancer. It requires either:

Increased metabolic activity, such as FDG (radio-labelled glucose) uptake by tumours
Receptor expression, such as prostate specific membrane antigen (PSMA) or estrogen receptor (FES) binding

The reliance on tumour biology means that in some cases tumour detection can be affected if a tumour becomes less metabolically active or loses receptor expression over time.

In contrast, MRI does not rely on receptor status or metabolic activity. Instead, MRI detects tumours through a combination of anatomical and functional sequences which highlights abnormality in:

Tissue structure
Cellular density
Water diffusion within tissues
Perfusion, or blood supply (using IV contrast)

This can be particularly useful where tumour biology is evolving, or where receptor-based imaging may become less reliable over time. Additionally, these benefits means MRI does not require prior knowledge of a cancer subtype or receptor profile to identify suspicious lesions making it more suitable for tumour surveillance, or for novel cancer screening.

MRI and PET Are Complementary, Not Competing

Although it is natural to ask “which one is best”, it is important to highlight that MRI and other modalities such as PET and CT are complementary, not completing, particularly for oncology staging or tumour surveillance.

In practice, they answer different questions. PET provides insight into tumour activity and receptor behaviour. It is often the first line of imaging for most tumour types. In many situations, whole-body MRI can be useful to provide detail about structure, tissue characteristics, and cellular patterns, independent of receptor status or metabolic activity.

There are situations where PET is essential. There are others where MRI adds clarity that PET cannot provide. In many cases, the most effective approach is to use both in a coordinated way, particularly where the goal is to balance sensitivity, specificity, and confidence in decision-making.

For example, some individuals with support by their treating oncologist, may opt to have a PET/CT followed by full-body MRI for co-registration of lesions between the modalities. This means tumour burden can be compared, and followed by full-body MRI to minimise the ionising radiation burden

Who Can Refer for Oncology Full Body MRI in Australia?

In Australia, a referral for whole-body MRI can be provided by either a medical specialist, such as a medical oncologist, or a general practitioner (GP).

If you are already under the care of an oncologist, it is generally preferable for the referral to come from them. This is because your oncologist is responsible for interpreting the results of your imaging in the context of your cancer journey and deciding whether any findings will influence treatment. Having them involved helps ensure the scan is answering a clear clinical question and that the results can be acted on appropriately.

That said, a GP can still refer for an cancer staging or surveillance full body MRI in Australia. This may be relevant if imaging is being explored outside of a formal oncology pathway, or if someone is seeking additional information or a second perspective.

Not All Imaging Is Equal

Imaging can appear standardised from the outside. In reality, there is meaningful variability between providers, particularly in full-body MRI where there are no widely accepted international standards for image acquisition or reporting. Differences can arise from:

Scanner hardware, strength (1.5T vs 3T) and calibration
Technical experience in MRI acquisition
Image protocols (inclusion of quality, high-fidelity sequences, such as DWIBS)
Resolution and signal quality
Radiologist experience with multi-organ cancer or whole-body imaging

These factors become particularly important in oncology, where decisions are often based on subtle changes over time. Importantly, not all providers offering full-body screening MRI are set up to perform imaging for oncology purposes.

This is because full-body MRI for cancer staging and monitoring requires specific protocols, including diffusion-weighted imaging and intravenous contrast, applied consistently within a clinically validated framework and supported by experience in interpreting oncologic imaging patterns.

Ultimately, what matters most is not just who writes the referral, but how well the imaging is integrated into your overall care. Scans are most useful when the reason for imaging is clearly defined, and when the results can be interpreted alongside your previous imaging and treatment plan.

Expertise Matters More Than Subtype Familiarity

In clinical full body MRI scans, accurate interpretation is less about familiarity with a specific cancer subtype, and more about expertise in whole-body MRI itself. Although tumour biology and imaging appearance may differ between subtypes (e.g. ductal vs lobular breast cancer), detection of tumour sites relies on recognising patterns such as:

Restriction on diffusion imaging
Changes on ADC mapping
Perfusion characteristics on contrast sequences
Structural changes or appearance on anatomical sequences

These principles apply across many malignancies. The quality of acquisition and reporting plays a larger role than exposure to any single cancer type.

The Bigger Issue: Consistency Over Time

If there is one concept that is often underestimated, it is consistency in oncology imaging.

Cancer imaging is not just about identifying disease at a single point in time. It is about understanding change, particularly in response to treatment. Assessing change to tumour size or overall burden becomes difficult if different machines are used, protocols vary between scans, and reporting styles are inconsistent or varied radiologist experience.

In these situations, it can be challenging to determine whether an observed difference reflects true tumour change or technical variation. For individuals requiring imaging over time, it is often preferable, particularly in oncology settings, to:

Use the same imaging modality
Return to the same clinic
Maintain consistency in how scans are performed and reported

Choosing an imaging provider for cancer staging is not just a short-term decision. It is often a long-term commitment. This matters because follow-up imaging is typically performed at regular intervals, whether every three, six, or twelve months, and consistency over time is important.

This does not mean patients cannot change imaging modalities or providers during treatment. However, when a switch occurs, any differences seen on the new scan may need to be interpreted with some caution, as they can reflect variation in technique rather than true change.

What This Means for Patients in Australia

If you are considering whole-body MRI as part of your cancer care, a few practical considerations can help guide the decision:

Think beyond the initial scan. Ongoing access to the same provider may be important, including any out-of-pocket costs (e.g. interstate travel costs)
Speak to your treating oncologist to share your preferences and discuss your imaging options.
Understand that different modalities may be used together (PET/CT plus full-body MRI), not interchangeably at all imaging points in your cancer journey.

Most importantly, imaging decisions should be made in consultation with your treating team.

Book a Full Body MRI for cancer staging in Australia

Full-body MRI scans performed as part of the Whole Body MRI™ packages are designed for oncology use, with protocols focused on high resolution and image fidelity.

If you would like to learn more or book a scan, contact our Gold Coast partner clinic, MBR Health (formerly Mermaid Beach Radiology) who can guide you through the booking process process and referral requirements.

Frequently Asked Questions

See below some of our most commonly asked questions about full body MRI for cancer staging. For a complete list of frequently asked questions, visit our FAQ page.

Can full body MRI be used if I already have cancer?

Yes. Full body MRI can be used in oncology for staging, monitoring treatment response, and ongoing surveillance. It may be used on its own or alongside other imaging such as PET/CT, depending on the clinical scenario and the question being asked.

How does whole-body MRI differ from PET/CT?

The two modalities assess different aspects of cancer and the way they make images.

PET imaging relies on tumour biology, such as metabolic activity or receptor expression. MRI does not rely on these factors and instead evaluates tissue structure, cellular density, and diffusion characteristics. Because of this, the modalities are often complementary rather than interchangeable.

Additionally, MRI differs from PET as it does not use ionising radiation, rather relies on strong magnets, radio-waves and advanced computer systems to generate images. For more information on the differences, particularly as they related to cancer screening, visit our blog “PET/CT vs Whole Body MRI: Which is Best”.

Do I need a referral for a whole-body MRI in Australia?

Yes. In Australia, a referral can be provided by either a GP or a specialist doctor such as a medical oncologist.

If you are under active cancer care, it is generally preferable for your oncologist to be involved so that the imaging aligns with your treatment plan and can be interpreted in the appropriate clinical context.

To learn more about referral requirements, visit our resource article “Why We Require a Referral for Full Body MRI Scans”

Can patients from New Zealand be referred for whole-body MRI in Australia?

Yes. Patients from New Zealand can be referred for a Whole Body MRI oncology scan.

A referral can be provided by a GP or specialist in New Zealand. Imaging can then be coordinated for patients who choose to travel for assessment.

Do I need an Australian doctor to refer me if I am from New Zealand?

No. A referral from a New Zealand GP or specialist Doctor is generally sufficient.

If needed, the team can provide guidance on referral requirements prior to booking.

Can I switch from PET/CT to full body MRI during treatment?

Yes, this is possible. However, switching modalities can introduce variability. Differences between scans may reflect changes in technique rather than true tumour behaviour, so findings may need to be interpreted with caution, particularly when comparing with prior imaging.

Can full body MRI be used for cancer screening in Australia?

Yes, full body MRI can be used as an elective cancer screening tool, and is increasingly offered in that context. However, it is important to understand that the underlying techniques used in full body MRI are derived from oncology imaging, where they are applied for cancer detection, staging, and monitoring.

While screening may identify unexpected findings, its reliability and effectiveness depends on how the scan is performed, the protocols used, and how results are interpreted. Not all full-body MRI services apply the same standards used in oncology, which can influence reliability.

Does an oncology Full Body MRI use contrast?

In most cases, yes. The team at Whole Body MRI and MBR Health perform our full-body MRI with intravenous (IV) contrast.

Contrast is used alongside diffusion-weighted imaging to improve lesion detection and characterisation (perfusion), and to provide more complete assessment of disease, including tumour kinetics and treatment response.

Download PDF

Can You Use Whole Body MRI If You Have Cancer?